Last reviewed · How we verify
Double Dose Quadrivalent Influenza Vaccine
A quadrivalent influenza vaccine administered at double the standard dose to enhance immune response and protective antibody generation against four influenza virus strains.
A quadrivalent influenza vaccine administered at double the standard dose to enhance immune response and protective antibody generation against four influenza virus strains. Used for Influenza prevention in adults (Phase 3 investigational).
At a glance
| Generic name | Double Dose Quadrivalent Influenza Vaccine |
|---|---|
| Sponsor | Hospital Israelita Albert Einstein |
| Drug class | Inactivated influenza vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
The vaccine contains inactivated antigens from four influenza virus strains (two A subtypes and two B lineages) at twice the typical antigen dose per strain. The increased antigen load is designed to stimulate a more robust humoral and cellular immune response, potentially improving seroconversion rates and antibody titers, particularly in populations with diminished immune responses such as elderly or immunocompromised individuals.
Approved indications
- Influenza prevention in adults (Phase 3 investigational)
Common side effects
- Injection site pain or erythema
- Myalgia
- Fatigue
- Headache
- Low-grade fever
Key clinical trials
- Influenza Vaccine (Split Virion), Inactivated, Quadrivalent in Pregnant Women (PHASE3)
- A Clinical Trial of an Quadrivalent Influenza Virus Subunit Vaccine in Chinese Children Aged 6 to 35 Months (PHASE3)
- Study to Assess the Safety and Immunogenicity of Monovalent mRNA NA Vaccine in Adult Participants 18 Years of Age and Older (PHASE1)
- A Phase III Clinical Trial of Quadrivalent Influenza Vaccine in Healthy Subjects Aged 6 to 35 Months (PHASE3)
- A Study on the Safety and Immunogenicity of Hexavalent Influenza mRNA Vaccine in Adult Participants 50 Years of Age and Older (PHASE1, PHASE2)
- Clinical Trial to Evaluate the Immunogenicity of an Adjuvanted Influenza Vaccine Among HCP (PHASE3)
- A Study of an Ad26.RSV.preF-based Vaccine and High-dose Seasonal Influenza Vaccine, With and Without Coadministration, in Adults Aged 65 Years and Older (PHASE3)
- A Study of Ad26.COV2.S and Influenza Vaccines in Healthy Adults (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: